On July 9, 2025, Rhythm Pharmaceuticals announced positive topline results from its Phase 2 trial of bivamelagon, showing statistically significant BMI reductions of up to -9.3% in patients with hypothalamic obesity, indicating it is effective and tolerable. The trial results suggest bivamelagon may perform similarly to the current therapy, setmelanotide, in comparable populations.